naquotinib + midazolam

Naquotinib + midazolam is a non-branded combination of two distinct pharmaceuticals: naquotinib (a third-generation small molecule EGFR tyrosine kinase inhibitor under investigation for treatment of non-small cell lung cancer with EGFR mutations) and midazolam (a benzodiazepine widely used as a probe for CYP3A-mediated metabolism, and clinically as a short-acting sedative and anxiolytic). In clinical pharmacology, this combination is utilized for drug–drug interaction studies; midazolam is administered to assess how naquotinib may modulate cytochrome P450 3A activity and thus the metabolism of co-administered drugs. Naquotinib acts chiefly as an irreversible inhibitor of the epidermal growth factor receptor (EGFR) with activating mutations. Midazolam functions as a positive allosteric modulator at the gamma-aminobutyric acid type A receptor (GABA_A receptor), enhancing the inhibitory effects of GABA, and is metabolized primarily by CYP3A4. No evidence currently indicates commercial co-formulation; both drugs maintain independent indications and mechanisms, but their combination is purposefully used in clinical studies for evaluating interaction risk, especially regarding altered CYP3A4 activity.